Four prestigious MRIdian hospital centers pooled their data after similarly treating a small number of pancreatic cancer patients and found that when using the MRIdian system and applying daily changes, they were able to deliver higher doses of radiation to the tumor, leading to longer overall survival. This promising data was presented just weeks ago at the European Society for Radiotherapy and Oncology (ESTRO) conference, and as a result, ViewRay plans to support a multi-center, prospective clinical trial. Patients diagnosed with pancreatic cancer who are not eligible for surgery will be considered for this study.
More information can be found in this recent press release and additional details will be announced as the study develops:
Illustration courtesy of the National Institute of Health